Skip to main content
Research funding

Team of international scientific experts to advise on £50 million investment into type 1 diabetes research

The Type 1 Diabetes Grand Challenge – a partnership between the Steve Morgan Foundation, Diabetes UK and JDRF UK– has successfully appointed 17 leading international scientists to advise on its £50 million investment into type 1 diabetes research.
Breakthrough T1D profile picture
Kate Gerrard 22 November 2022

A grand appointment

The Type 1 Diabetes Grand Challenge – a partnership between the Steve Morgan Foundation, Diabetes UK and JDRF UK– has successfully appointed 17 leading international scientists to advise on its £50 million investment into type 1 diabetes research.

The scientists have joined one of three independent Scientific Advisory Panels each advising on a research area identified as having the greatest potential to transform treatments for type 1 diabetes:

  • The root causes of type 1 diabetes Panel, led by Professor Chantal Mathieu
  • The novel insulins Panel, led by Dr Tim Heise
  • The beta cell replacement Panel, led by Professor Matthias Hebrok

All three Panels are Chaired by Professor Simon Heller, a world-renowned diabetes specialist.

Further information on the Grand Challenge’s scope and ambition, and membership of the Scientific Advisory Panels, can be found on the Partnership’s new website.

The Grand Challenge website

The site also features latest Grand Challenge news, information about funding opportunities and funded projects. When research projects are underway it will also demonstrate and celebrate their impact.

Rachel Connor, Director of Research Partnerships at JDRF UK said: “We’re delighted to welcome so many globally renowned scientists, who are already giving us the benefit of their insight and expertise as we shape this Grand Challenge. They are ensuring the research we support through this game-changing partnership will best meet the needs of people living with type 1. The calibre of membership we’ve been able to attract to the new panels is testament to how thrilling the new research, supported by the partnership, will be.”

Dr Elizabeth Robertson, Director of Research at Diabetes UK said: “We are honoured to have so many of the world’s most distinguished diabetes researchers advising the Type 1 Diabetes Grand Challenge. Their expertise will help to ensure that every penny of the Steve Morgan Foundation’s £50 million gift is invested in bold, innovative research with the greatest potential to improve the lives of people with type 1 diabetes.

“We’re delighted to see the global research community united in their support of the Type 1 Diabetes Grand Challenge and look forward to seeing new, exciting research focusing on accelerating progress towards a cure for type 1 diabetes get underway next year.”

The new website can be found at type1diabetesgrandchallenge.org.uk

Related news

Read more
ADA 2026 logo
Breakthrough T1D
8 June 2026

12 of 12 trial participants are no longer injecting insulin, thanks to new immunosuppressive drug tegoprubart

New data presented this week at the American Diabetes Association’s (ADA) 86th Scientific Sessions shows incredible promise: all 12 participants in the Eledon trial, testing the immunosuppressive drug tegoprubart, are no longer injecting insulin.

Read more
Breakthrough T1D
2 June 2026

Steve Morgan Foundation funding to boost psychological support for young people with T1D

The Steve Morgan Foundation has donated £280,000 to Breakthrough T1D and DigiBete to expand Coping with Diabetes online tool.

Read more
Breakthrough T1D
30 March 2026

Three key themes for ATTD 2026

Discussing the main themes from this year's Advanced Technologies & Treatments for Diabetes conference – early detection, cellular cures and disease-modifying therapies.

Read more
Scientist researcher woman in white coat using microscope in laboratory
Breakthrough T1D
16 March 2026

Positive 14-month follow-up data from Sana Biotechnology gives hope for people with type 1 diabetes

These lab-engineered cells have been able to evade the immune system and produce insulin for 14 months without the need for immunosuppression.